c.h. robinson worldwide inc. - CHRW
CHRW
Close Chg Chg %
167.66 -5.56 -3.32%
Open Market
162.10
-5.56 (3.32%)
Volume: 876.31K
Last Updated:
Mar 27, 2026, 2:55 PM EDT
Company Overview: c.h. robinson worldwide inc. - CHRW
CHRW Key Data
| Open $166.95 | Day Range 161.43 - 167.19 |
| 52 Week Range 84.68 - 203.34 | Market Cap $19.89B |
| Shares Outstanding 118.62M | Public Float 117.89M |
| Beta 0.90 | Rev. Per Employee N/A |
| P/E Ratio 34.70 | EPS $4.88 |
| Yield 148.51% | Dividend $0.63 |
| EX-DIVIDEND DATE Mar 6, 2026 | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.63M |
CHRW Performance
| 1 Week | -0.72% | ||
| 1 Month | -9.50% | ||
| 3 Months | 1.84% | ||
| 1 Year | 65.79% | ||
| 5 Years | 71.61% |
CHRW Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
28
Full Ratings ➔
An error occurred while fetching the data.
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for C.h. Robinson Worldwide Inc. - CHRW
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 24.70B | 17.60B | 17.72B | 16.23B | |
Sales Growth
| +6.90% | -28.75% | +0.73% | -8.42% | |
Cost of Goods Sold (COGS) incl D&A
| 22.83B | 16.44B | 16.39B | 14.87B | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 92.78M | 98.98M | 97.16M | 102.82M | |
Depreciation
| 38.10M | 39.57M | 35.97M | 32.52M | |
Amortization of Intangibles
| 54.67M | 59.42M | 61.19M | 70.30M | |
COGS Growth
| +6.20% | -27.98% | -0.28% | -9.27% | |
Gross Income
| 1.87B | 1.16B | 1.33B | 1.36B | |
Gross Income Growth
| +16.27% | -38.12% | +15.15% | +2.00% | |
Gross Profit Margin
| +7.57% | +6.58% | +7.52% | +8.37% |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 603.41M | 604.63M | 573.29M | 563.38M | |
Research & Development
| - | - | - | - | - |
Other SG&A
| 603.41M | 604.63M | 573.29M | 563.38M | |
SGA Growth
| +14.64% | +0.20% | -5.18% | -1.73% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | 39.46M | 45.73M | - |
EBIT after Unusual Expense
| 1.27B | 513.19M | 713.60M | 795.88M | |
Non Operating Income/Expense
| (22.92M) | (13.80M) | (48.50M) | (10.32M) | |
Non-Operating Interest Income
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 77.10M | 90.20M | 85.90M | 63.10M | |
Interest Expense Growth
| +28.89% | +16.99% | -4.77% | -26.54% | |
Gross Interest Expense
| 77.10M | 90.20M | 85.90M | 63.10M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| 1.17B | 409.19M | 579.20M | 722.46M | |
Pretax Income Growth
| +14.13% | -64.93% | +41.55% | +24.73% | |
Pretax Margin
| +4.72% | +2.33% | +3.27% | +4.45% | |
Income Tax
| 226.24M | 84.06M | 113.51M | 135.38M | |
Income Tax - Current - Domestic
| 186.66M | 59.16M | 158.89M | 85.79M | |
Income Tax - Current - Foreign
| 97.15M | 62.43M | 32.88M | 41.59M | |
Income Tax - Deferred - Domestic
| (51.98M) | (26.60M) | (94.08M) | 12.30M | |
Income Tax - Deferred - Foreign
| (5.58M) | (10.94M) | 15.82M | (4.30M) | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| 940.52M | 325.13M | 465.69M | 587.08M | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| 940.52M | 325.13M | 465.69M | 587.08M | |
Net Income Growth
| +11.40% | -65.43% | +43.23% | +26.07% | |
Net Margin Growth
| +3.81% | +1.85% | +2.63% | +3.62% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| 940.52M | 325.13M | 465.69M | 587.08M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 940.52M | 325.13M | 465.69M | 587.08M | |
EPS (Basic)
| 7.4797 | 2.7425 | 3.8871 | 4.8825 | |
EPS (Basic) Growth
| +17.37% | -63.33% | +41.74% | +25.61% | |
Basic Shares Outstanding
| 125.74M | 118.55M | 119.81M | 120.24M | |
EPS (Diluted)
| 7.397 | 2.7167 | 3.8589 | 4.8319 | |
EPS (Diluted) Growth
| +17.26% | -63.27% | +42.04% | +25.21% | |
Diluted Shares Outstanding
| 127.15M | 119.68M | 120.68M | 121.50M | |
EBITDA
| 1.36B | 651.63M | 856.50M | 898.69M | |
EBITDA Growth
| +15.87% | -52.07% | +31.44% | +4.93% | |
EBITDA Margin
| +5.51% | +3.70% | +4.83% | +5.54% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 196.25 | |
| Number of Ratings | 28 | Current Quarters Estimate | 1.262 | |
| FY Report Date | 03 / 2026 | Current Year's Estimate | 6.055 | |
| Last Quarter’s Earnings | 1.23 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 5.09 | Next Fiscal Year Estimate | 7.181 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 24 | 24 | 25 | 25 |
| Mean Estimate | 1.26 | 1.53 | 6.05 | 7.18 |
| High Estimates | 1.40 | 1.90 | 6.50 | 8.00 |
| Low Estimate | 1.14 | 1.36 | 5.30 | 5.40 |
| Coefficient of Variance | 4.84 | 6.38 | 3.97 | 6.79 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 13 | 13 | 13 |
| OVERWEIGHT | 3 | 3 | 3 |
| HOLD | 9 | 9 | 9 |
| UNDERWEIGHT | 2 | 1 | 1 |
| SELL | 1 | 2 | 2 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for C.h. Robinson Worldwide Inc. - CHRW
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for C.h. Robinson Worldwide Inc. - CHRW
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Feb 20, 2026 | Michael Castagnetto Pres, NAST | 32,479 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $176.01 per share | 5,716,628.79 |
| Feb 20, 2026 | Michael J. Short President, Global Forwarding | 44,298 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $176.01 per share | 7,796,890.98 |
| Feb 20, 2026 | Angela K. Freeman CHRO and ESG Officer | 48,824 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $176.01 per share | 8,593,512.24 |
| Feb 20, 2026 | Arun Rajan Chief Strat & Innov Officer | 124,626 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $176.01 per share | 21,935,422.26 |
| Aug 13, 2025 | Edward G. Feitzinger Director | 1,270 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jul 11, 2025 | Damon Lee Chief Financial Officer | 37,737 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $95.17 per share | 3,591,430.29 |
| Apr 4, 2025 | Michael H. McGarry Director | 1,535 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 4, 2025 | Paula C. Tolliver Director | 14,443 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 4, 2025 | Paige K. Robbins Director | 1,535 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 4, 2025 | Henry J. Maier Director | 5,733 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 4, 2025 | James Jay Barber Director | 4,315 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 4, 2025 | Timothy C. Gokey Director | 22,863 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 4, 2025 | Mary J. Steele Guilfoile Director | 19,620 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 4, 2025 | Mark A. Goodburn Director | 9,718 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 4, 2025 | Henry Ward Winship Director | 5,733 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 4, 2025 | Jodeen A. Kozlak Director | 26,074 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 4, 2025 | Kermit R. Crawford Director | 7,970 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |